ProtoKinetix, Inc. (PKTX) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US7437221002

Price
0.00 USD
Market cap
824,260.30 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

ProtoKinetix, Inc. financials

Fiscal year2025
EBIT-393,650.00 USD
Net income-393,650.00 USD
Diluted EPS – continuing operations0.00 USD

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ProtoKinetix, Inc.

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications, such as targeted health care solutions, as well as AAGPs are used in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Dalton, Ohio.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.